* Emtricitabine–tenofovir disoproxil fumarate (Truvada), a combination of two nucleoside analog HIV-1 reverse transcriptase inhibitors, is the first drug to be approved for the prevention of HIV infection in those who are at high risk for contracting HIV from a sexual partner.
* Truvada should be used as part of a comprehensive plan for prevention of disease transmission. It needs to be taken daily to achieve its therapeutic effect.
* It's important that a negative HIV status be confirmed before a patient begins therapy.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org.